Gu et al. found that ABT-199 (a BH3 mimetic that specifically inhibits BCL-2) only slightly enhanced AEC2 apoptosis compared with vehicle controls when given during bleomycin-induced fibrosis development (days 12–21) (43). This evidence concerns the gene BCL2 and fibrosis.